基于MSC的非COVID-19 ARDS治疗方法的图书统计分析
Shengyu Huang1, Dan Wang2, Yusong Wang3
1Medical Center of Burn Plastic and Wound Repair, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, 330006, Jiangxi Province, China.
对急性呼吸困扰综合征 (ARDS) 中介质干细胞 (MSCs) 的研究显示,MSC衍生物和带/胎盘来源的转移呈现下降趋势. 内输送需要进一步验证.
科学领域:
- 再生医学是一种再生医学.
- 肺部医学 肺部医学
- 生物技术是生物技术.
背景情况:
- 急性呼吸困扰综合征 (ARDS) 缺乏特定的治疗方法,这对临床提出了重大挑战.
- 介质干细胞 (MSC) 由于其免疫调节,抗炎和抗纤维性质,显示出对ARDS的治疗潜力.
- 在非COVID-19 ARDS中MSC疗效的临床证据仍然有限.
研究的目的:
- 对非COVID-19 ARDS中介质干细胞 (MSCs) 的研究趋势进行文献计量分析.
- 确定基于MSC的ARDS研究的重点领域,新兴趋势和未来方向.
主要方法:
- 在 Web of Science,Scopus 和 PubMed 上进行系统的文献搜索.
- 使用R Studio进行文献计量分析,分析出版趋势和指标.
- 识别和分析了244篇原创研究文章.
主要成果:
- 对非COVID-19 ARDS的MSC的研究从2007年开始增加,但在2019年之后下降.
- 中国学者为这项研究贡献了很大一部分 (131/244项研究).
- 焦点正在转向MSC衍生品,带/胎盘MSC在骨髓MSC上获得突出地位;静脉输送仍然占主导地位.
结论:
- 对于非COVID-19 ARDS疗法,需要进一步的研究和投资.
- MSC衍生物证明了临床疗效,表明它们未来的治疗作用.
- 带/胎盘MSCs已准备好取代骨髓MSCs;肌内输送需要进一步验证.
更多相关视频
11:02Identification and Quantification of Deranged Metabolites in Critically Ill Patients Using NMR-Based Metabolomics
Published on: November 29, 2024
09:36Halogenated Agent Delivery in Porcine Model of Acute Respiratory Distress Syndrome via an Intensive Care Unit Type Device
Published on: September 24, 2020
相关概念视频
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Mesenchymal Stem Cells
Acute Respiratory Failure-V
Ensure that patients are monitored continuously for their response to therapy, including changes in...
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
